United States - English - NLM (National Library of Medicine)

cronus pharma llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases the incidence

United States - English - NLM (National Library of Medicine)

cronus pharma llc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: dogs: skin infections (wounds and abscesses) due to coagulase positive staphylococci (staphylococcus aureus or staphylococcus intermedius). deep wounds and abscesses due to bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens. dental infections due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens. osteomyelitis due to staphylococcus aureus, bacteroides fragilis, prevotella melaninogenicus, fusobacterium necrophorum and clostridium perfringens. clindamycin hydrochloride capsules, usp are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. because of potential adverse gastrointestinal e

United States - English - NLM (National Library of Medicine)

cronus pharma llc - carprofen (unii: ffl0d546ho) (carprofen - unii:ffl0d546ho) - carprofen chewable tablets are indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. carprofen chewable tablets should not be used in dogs exhibiting previous hypersensitivity to carprofen.

United States - English - NLM (National Library of Medicine)

cronus pharma llc - atipamezole hydrochloride (unii: 2w4279571x) (atipamezole - unii:03n9u5jaf6) - cropamezole™ is indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs. since atipamezole is always used concomitantly with dexmedetomidine or medetomidine, it should not be used in dogs with the following conditions: cardiac disease, respiratory disorders, liver or kidney diseases, dogs in shock, severely debilitated dogs, or dogs stressed due to extreme heat, cold or fatigue. administration of atipamezole is contraindicated in dogs with a known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

cronus pharma llc - amoxicillin anhydrous (unii: 9em05410q9) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium for oral suspension drops are indicated in the treatment of: dogs: skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus , non-β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., and e. coli . periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. amoxicillin and clavulanate potassium for oral suspension has been shown to be clinically effective for treating cases of canine periodontal disease. cats: skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus, non-β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., e. coli, pasteurella multocida, and pasteurella spp. urinary tract infection

United States - English - NLM (National Library of Medicine)

cronus pharma llc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 25 mg in 1 ml - clindamycin hydrochloride oral solution (for use in dogs and cats) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: dogs: skin infections (wounds and abscesses)  due to coagulase positive staphylococci  (staphylococcus aureus  or staphylococcus intermedius ). deep wounds and abscesses  due to bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . dental infections due to staphylococcus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . osteomyelitis  due to staphylococcus aureus , bacteroides fragilis , prevotella melaninogenicus , fusobacterium necrophorum and clostridium perfringens . cats: skin infections (wounds and abscesses) due to staphylococcus aureus , staphylococcus intermedius , streptococcus spp. deep wounds and abscesses due  to clostridium perfringens and bacteroides fragilis . dental infections  due to staphylococcus aureus , staphylococcus intermedius , streptococcus spp., clostridium perfringens and bacteroides fragilis . clindamycin hydrochloride oral solution is contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

United States - English - NLM (National Library of Medicine)

cronus pharma llc - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - dog: furosemide is an effective diuretic possessing a wide therapeutic range. pharmacologically it promotes the rapid removal of abnormally retained extracellular fluids. the rationale for the efficacious use of diuretic therapy is determined by the clinical pathology producing the edema. furosemide syrup 1% is indicated for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema. the continued use of heart stimulants, such as digitalis or its glycosides, is indicated in cases of edema involving cardiac insufficiency. furosemide syrup 1% is a highly effective diuretic-saluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. therefore, the dosage and schedule may have to be adjusted to the patients' needs. the animal should be observed for early signs of electrolyte imbalance, and corrective measures administered. early signs of electrolyte imbalance are: increased thirst, lethargy, drowsiness

United States - English - NLM (National Library of Medicine)

cronus pharma llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cephalexin capsules are contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. risk summary available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (mrhd) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data human data while available studies cannot definitively establish the absence of risk, published data from epidemiologic studies and postmarketing case reports over several decades have not identified a consistent association with cephalosporin use, including cephalexin, during pregnancy, and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. animal data in animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the mrhd) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. in a pre-and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from day 15 of pregnancy to litter day 21 showed no adverse effects on parturition, litter size, or growth of offspring. risk summary data from a published clinical lactation study reports that cephalexin is present in human milk. the relative infant dose (rid) is considered to be <1% of the maternal weight adjusted dose. there are no data on the effects of cephalexin on the breastfed child or on milk production. the development of health benefits of breastfeeding should be considered along with the mother’s clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition. the safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [see dosage and administration (2.2)]. of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [see warnings and precautions (5.4)]. cephalexin should be administered with careful monitoring in the presence of renal impairment (creatinine clearance < 30 ml/min, with or without dialysis). under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [see dosage and administration (2.3)] . monitor patients longer for toxicity and drug interactions due to delayed clearance.

United States - English - NLM (National Library of Medicine)

cronus pharma llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - indications: amoxicillin and clavulanate potassium tablets are indicated in the treatment of: dogs: skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus, non- β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., and e. coli. periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. amoxicillin and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease. cats: skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus, non- β-lactamase-producing staphylococcus aureus, staphylococcus spp., streptococcus spp., e. coli, and pasteurella spp. urinary tract infections (cystitis) due to susceptible st

United States - English - NLM (National Library of Medicine)

cronus pharma llc - doramectin (unii: kgd7a54h5p) (doramectin - unii:kgd7a54h5p) - cattle: doraject injectable solution is indicated for the treatment and control of the following harmful species of gastrointestinal roundworms, lungworms, eyeworms, grubs (see precautions), sucking lice (see precautions), and mange mites. consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. doraject™ injectable solution has been proved to effectively control infections and to protect cattle from reinfection with cooperia oncophora and haemonchus placei for 14 days, ostertagia ostertagi for 21 days, and c. punctata , oesophagostomum radiatum , and dictyocaulus viviparus for 28 days after treatment. swine: doraject™ injectable solution is indicated for the treatment and control of the following species of gastrointestinal roundworms, lungworms, kidney worms, sucking lice (see precautions), and mange mites. consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.  gastrointestinal roundworms (adults and fourth stage larvae) ascaris suum   oesophagostomum dentatum   oesophagostomum quadrispinulatum 1   strongyloides ransomi 1   hyostrongylus  rubidus1 1 adults  lungworms (adults) metastrongylus  spp. kidney worms (adults) stephanurus dentatus mange mites (adults and immature stages) sarcoptes scabiei var. suis sucking lice (adults and immature stages) haematopinus suis